Skip to main content
TipRanks
Go Ultimate75% OFF

Braveheart Bio, Inc. (BRVE) AI Stock Analysis

23 Followers
BRVE

Braveheart Bio, Inc.

(NASDAQ:BRVE)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Negative Factors

Braveheart Bio, Inc. (BRVE) vs. SPDR S&P 500 ETF (SPY)

-50%-40%-30%-20%-10%0%10%20%30%BRVE-37.82%SPY+13.11%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$1.33B
Dividend Yield
―
Average Volume (3M)
460.31K
Price to Earnings (P/E)
-6.4
Beta (1Y)
-0.04
Revenue Growth
―
EPS Growth
―
Country
US
Employees
49
Sector
General
Sector Strength
55
Industry
Biotechnology

Braveheart Bio, Inc. Business Overview & Revenue Model

Company Description

Braveheart Bio, Inc. engages in the development of therapeutics to treat hypertrophic cardiomyopathy. Its lead product candidate is BHB-1839 which is a small-molecule cardiac myosin inhibitor. The company was founded on May 13,2024 and is headquarter...

Braveheart Bio, Inc. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

BRVE against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
ANABANAB61Neutral$1.36B7.14906.99%―13.04%―
XNCRXNCR61Neutral$2.59B-22.05-21.29%―33.55%11.51%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
ZBIOZBIO51Neutral$1.88B-2.76-208.91%―-26.67%-121.60%
NUVBNUVB49Neutral$1.38B-9.91-49.11%―654.19%39.07%
ZYMEZYME48Neutral$1.80B38.3222.48%―97.78%―

* General Sector Average

Performance Comparison

-50%0%50%100%150%BRVEXNCRANABZYMENUVBZBIODec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
BRVE and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
BRVEBraveheart Bio, Inc.18.53-11.27-37.82%
XNCRXencor Inc.34.3918.82120.80%
ANABAnaptysBio47.0621.9687.48%
ZYMEZymeworks26.042.229.32%
NUVBNuvation Bio Inc3.78-3.23-46.08%
ZBIOZenas BioPharma, Inc.26.42-8.42-24.17%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.